U.S. Markets open in 8 hrs 43 mins
  • S&P Futures

    3,615.75
    -20.75 (-0.57%)
     
  • Dow Futures

    29,672.00
    -202.00 (-0.68%)
     
  • Nasdaq Futures

    12,227.25
    -30.25 (-0.25%)
     
  • Russell 2000 Futures

    1,838.20
    -14.80 (-0.80%)
     
  • Crude Oil

    44.88
    -0.65 (-1.43%)
     
  • Gold

    1,772.60
    -15.50 (-0.87%)
     
  • Silver

    22.12
    -0.52 (-2.29%)
     
  • EUR/USD

    1.1976
    +0.0006 (+0.0479%)
     
  • 10-Yr Bond

    0.8420
    0.0000 (0.00%)
     
  • Vix

    20.84
    -0.41 (-1.93%)
     
  • GBP/USD

    1.3343
    +0.0029 (+0.2148%)
     
  • USD/JPY

    103.8670
    -0.2180 (-0.2094%)
     
  • BTC-USD

    18,521.69
    -11.20 (-0.06%)
     
  • CMC Crypto 200

    365.45
    +27.95 (+8.28%)
     
  • FTSE 100

    6,367.58
    +4.65 (+0.07%)
     
  • Nikkei 225

    26,441.00
    -203.71 (-0.76%)
     

CLASS ACTION UPDATE for BMRN, CACC and LVS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

·4 min read

NEW YORK, NY / ACCESSWIRE / October 26, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

BMRN Shareholders Click Here: https://www.zlk.com/pslra-1/biomarin-pharmaceutical-inc-loss-submission-form?prid=10469&wire=1
CACC Shareholders Click Here: https://www.zlk.com/pslra-1/credit-acceptance-corporation-loss-submission-form?prid=10469&wire=1
LVS Shareholders Click Here: https://www.zlk.com/pslra-1/las-vegas-sands-corp-loss-submission-form?prid=10469&wire=1

* ADDITIONAL INFORMATION BELOW *

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

BMRN Lawsuit on behalf of: investors who purchased February 28, 2020 - August 18, 2020
Lead Plaintiff Deadline : November 24, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/biomarin-pharmaceutical-inc-loss-submission-form?prid=10469&wire=1

According to the filed complaint, during the class period, BioMarin Pharmaceutical Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) differences between the Phase 1/2 and Phase 3 study of valoctocogene roxaparvovec, an investigational adenoassociated virus gene therapy, limited the reliability of the Phase 1/2 study to support valoctocogene roxaparvovec's durability of effect; (ii) as a result, it was foreseeable that the U.S. Food and Drug Administration would not approve the Biologics License Application for valoctocogene roxaparvovec without additional data; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Credit Acceptance Corporation (NASDAQ:CACC)

CACC Lawsuit on behalf of: investors who purchased November 1, 2019 - August 28, 2020
Lead Plaintiff Deadline : December 1, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/credit-acceptance-corporation-loss-submission-form?prid=10469&wire=1

According to the filed complaint, during the class period, Credit Acceptance Corporation made materially false and/or misleading statements and/or failed to disclose that: (i) the Company was topping off the pools of loans that they packaged and securitized with higher-risk loans; (ii) Credit Acceptance was making high-interest subprime auto loans to borrowers that the Company knew borrowers would be unable to repay; (iii) the borrowers were subject to hidden finance charges, resulting in loans exceeding the usury rate ceiling mandated by state law; (iv) Credit Acceptance took excessive and illegal measures to collect debt from defaulted borrowers; (v) as a result, the Company was likely to face regulatory scrutiny and possible penalties from various regulators or lawsuits; and (vi) that, as a result of the foregoing, Defendants positive statements about the Company's business, operations, and adherence to appropriate laws and regulations were materially misleading and/or lacked a reasonable basis.

Las Vegas Sands Corp. (NYSE:LVS)

LVS Lawsuit on behalf of: investors who purchased February 27, 2016 - September 15, 2020
Lead Plaintiff Deadline : December 21, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/las-vegas-sands-corp-loss-submission-form?prid=10469&wire=1

According to the filed complaint, during the class period, Las Vegas Sands Corp. made materially false and/or misleading statements and/or failed to disclose that: (i) weaknesses existed in Marina Bay Sands' casino control measures pertaining to fund transfers; (ii) the Marina Bay Sands' casino was consequently prone to illicit fund transfers that implicated, among other issues, the transfer of customer funds to unauthorized persons and potential breaches in the Company's anti-money laundering procedures; (iii) the foregoing foreseeably increased the risk of litigation against the Company, as well as investigation and increased oversight by regulatory authorities; (iv) Las Vegas Sands had inadequate disclosure controls and procedures; (v) consequently, all the foregoing issues were untimely disclosed; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/612345/CLASS-ACTION-UPDATE-for-BMRN-CACC-and-LVS-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders